KMB
Kimberly-Clark Corporation102.54
-0.26-0.25%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Costco diaper loss headwind disclosed
Q&A spotlighted a partial loss of diaper/pull-up distribution at a major North American club channel starting Q1, a 60bps full-year organic growth headwind already baked into Kimberly-Clark's in-line-to-ahead-of-2% category outlook. Management reaffirmed volume gains stem from value propositions across good/better/best tiers amid consumer pressure, with the strongest-ever innovation pipeline ramping back-half. Pricing softness traced to promo rephasing, club pack shifts, and strategic investments, not competitive weakness. Margins expand in 2026 via flat costs and 6% productivity. Club shift stings short-term. Confident tone persists; investors watch volume resilience and Kenview close.
Key Stats
Market Cap
34.03BP/E (TTM)
17.35Basic EPS (TTM)
5.91Dividend Yield
0.05%Recent Filings
10-K
FY2025 results
Kimberly-Clark's FY2025 continuing operations posted $16.4B net sales, down 2.1% y/y from divestitures like PPE and business exits, yet organic sales grew 1.7% on 2.5% volume gains across NA (1.8% organic) and IPC (1.7% organic). Operating profit fell 12.9% to $2.4B amid $348 in transformation charges, but adjusted profit held flat at $2.7B as productivity offset pricing and tariff pressures. Q4 momentum stayed solid with steady volume trends, while gross productivity hit ~$460. Debt stands at $7.2B; repurchased 1.1M shares for $141. Raw material volatility threatens quarterly margins.
8-K
K-C shareholders approve Kenvue deal
Kimberly-Clark stockholders approved the issuance of shares for its acquisition of Kenvue on January 29, 2026, with 239 million votes for versus 8 million against—96% of shares present. Stockholders resoundingly backed the deal. Closing awaits regulatory approvals in H2 2026, yet integration risks loom.
8-K
Strong Q4 organic growth
Kimberly-Clark reported Q4 net sales of $4.1B, down 0.6% but with 2.1% organic growth from 3.0% volume-plus-mix gains, offset by private label diaper exit. Adjusted operating profit jumped 13.1% to $629M on productivity; full-year adjusted EPS rose 3.2% to $7.53. Momentum builds. 2026 eyes mid-to-high single-digit adjusted operating profit growth, yet Kenvue integration risks loom.
8-K
Proxy supplement counters suits
Kimberly-Clark supplements its joint proxy ahead of January 29, 2026 stockholder votes on the Kenvue merger, addressing stockholder lawsuits alleging disclosure omissions in Wisconsin, New Jersey, and New York courts. Additions detail merger background, like Kenvue's June 2025 strategic committee and August NDA; financial advisors' analyses with Kenvue 2026E Adjusted EBITDA at $3,565M; and unaudited projections showing K-C standalone revenue rising to $19,013M by 2030E. Litigation risks persist, yet K-C board stands firm.
8-K
Recasts 10-K for IFP JV
IPO
Employees
Sector
Industry
CL
Colgate-Palmolive Company
78.95-0.48
CLX
Clorox Company (The)
99.82-1.90
COTY
Coty Inc.
3.27-0.01
EL
Estee Lauder Companies, Inc. (T
104.39+3.36
HNST
The Honest Company, Inc.
2.86+0.05
KVUE
Kenvue Inc.
17.25+0.04
NWL
Newell Brands Inc.
3.77+0.00
PG
Procter & Gamble Company (The)
145.21+0.08
PKG
Packaging Corporation of Americ
203.66-0.82
UL
Unilever PLC
64.33-0.71